NEW YORK (GenomeWeb News) - Genesis Genomics has received a CAN$311,735 (US$ 305,540) investment from the Ontario provincial government to fund its mitochondrial DNA-based diagnostic tests for cancer, the firm’s controller, Carole McCollum, told GenomeWeb News today.
The Thunder Bay, Ontario-based company will use the funds from the Northern Ontario Heritage Fund to continue to develop and commercialize a diagnostic test for prostate cancer and to develop an early-stage breast cancer test, McCollum said.
Last month, Genesis Genomics was awarded part of a CA$465,000 Natural Science and Engineering grant to work with Genoma and two Canadian universities to develop and sell a handheld device that would rapidly identify a species based on its DNA sequences.